Keeping Track: Cardio-Renal Drugs At Heart Of US FDA’s March Approval Binge

 
• By Bridget Silverman

Seven novel agents approved in March include one accelerated approval, two rare pediatric disease priority review vouchers, two breakthrough therapy designations and one regenerative medicine advance therapy designation.

Keeping Track Feature image
The US FDA approved seven new molecular entities and novel biologics in March. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers